全文获取类型
收费全文 | 6210篇 |
免费 | 503篇 |
国内免费 | 68篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 186篇 |
妇产科学 | 69篇 |
基础医学 | 788篇 |
口腔科学 | 167篇 |
临床医学 | 859篇 |
内科学 | 1343篇 |
皮肤病学 | 99篇 |
神经病学 | 528篇 |
特种医学 | 420篇 |
外科学 | 773篇 |
综合类 | 157篇 |
一般理论 | 2篇 |
预防医学 | 463篇 |
眼科学 | 55篇 |
药学 | 347篇 |
中国医学 | 6篇 |
肿瘤学 | 473篇 |
出版年
2021年 | 88篇 |
2020年 | 63篇 |
2019年 | 99篇 |
2018年 | 103篇 |
2017年 | 80篇 |
2016年 | 102篇 |
2015年 | 105篇 |
2014年 | 129篇 |
2013年 | 205篇 |
2012年 | 290篇 |
2011年 | 283篇 |
2010年 | 186篇 |
2009年 | 171篇 |
2008年 | 255篇 |
2007年 | 319篇 |
2006年 | 251篇 |
2005年 | 230篇 |
2004年 | 232篇 |
2003年 | 224篇 |
2002年 | 193篇 |
2001年 | 187篇 |
2000年 | 181篇 |
1999年 | 189篇 |
1998年 | 129篇 |
1997年 | 138篇 |
1996年 | 143篇 |
1995年 | 114篇 |
1994年 | 97篇 |
1993年 | 86篇 |
1992年 | 120篇 |
1991年 | 109篇 |
1990年 | 132篇 |
1989年 | 162篇 |
1988年 | 140篇 |
1987年 | 122篇 |
1986年 | 123篇 |
1985年 | 141篇 |
1984年 | 80篇 |
1983年 | 72篇 |
1982年 | 56篇 |
1981年 | 50篇 |
1980年 | 43篇 |
1979年 | 63篇 |
1978年 | 52篇 |
1977年 | 36篇 |
1976年 | 31篇 |
1975年 | 35篇 |
1974年 | 31篇 |
1973年 | 50篇 |
1969年 | 33篇 |
排序方式: 共有6781条查询结果,搜索用时 140 毫秒
1.
Jim Zhong Michael Gallagher Chris Hounslow Gareth Iball Tze Wah 《Diagnostic and interventional radiology (Ankara, Turkey)》2021,27(2):244
PURPOSEWe aimed to evaluate the effect on the radiation dose to the patient by reducing the tube current during the placement of the ablation needles (reduced dose group) compared with the patient doses delivered when scanning at the standard fully diagnostic level (full dose group) in computed tomography (CT)-guided percutaneous cryoablation.METHODSWe conducted a retrospective study of 103 patients undergoing cryoablation in a tertiary cancer center. Overall, 62 patients were scanned with standard exposure parameters (full dose group) set on a 64-slice multidetector CT scanner, while 41 patients were scanned on a reduced dose protocol. Dose levels were retrieved from the hospital picture and archiving communication system including the volumetric CT dose index (CTDIvol), total dose length product (DLP), length of cryoablation procedure, number of cryoablation needles and patient size. Wilcoxon Mann-Whitney (rank-sum) tests were used to compare the median DLP, CTDIvol and skin dose between the two groups.RESULTSMedian total DLP for the full dose group was 6025 mGy·cm (1909–13353 mGy·cm) compared with 3391 mGy·cm (1683–6820 mGy·cm) for the reduced dose group. The reduced dose group had a 44% reduction in total DLP and 42% reduction in total CTDIvol (p < 0.001). The estimated skin doses were 384 mGy for the full dose group and 224 mGy for the reduced dose group (42% reduction) (p < 0.001). At 12-month follow-up, the technical success for the full dose (n=62) was 97% with 2 patients requiring a further cryoablation treatment for residual tumor. The technical success for the reduced dose group (n=41) was 100%.CONCLUSIONCT dose reduction technique during image-guided cryoablation treatment of renal tumors can achieve significant radiation dose reduction whilst maintaining sufficient image quality.Renal cell carcinoma is the most common kidney cancer and has a rising incidence (1–4), with obesity and smoking being major risk factors (5–8).Image-guided ablation offers a more minimally invasive option compared with surgery and the current evidence base shows that it is a safe and effective treatment for T1a tumors, with a low rate of complications (9–11). The major advantage of cryoablation over other modalities is the ability to accurately visualize the iceball and therefore zone of ablation on intraprocedural imaging, either with computed tomography (CT) or magnetic resonance imaging (MRI) (12, 13). However, renal cryoablation involves the placement of more ablation probes and can have almost three times the radiation exposure compared with CT-guided radiofrequency ablation procedures (14).In addition to this substantial radiation dose per cryoablation, estimated to be between 32 and 39.7 mSv, the follow-up CT imaging will also add to the total radiation burden (15, 16). Whilst this level of radiation dose and associated stochastic risk may be a lesser concern in the older patients, greater consideration needs to be given to younger patients (<50 years old) and in patients requiring lifelong follow-up imaging, in particular those with hereditary diseases such as Von Hippel-Lindau syndrome (15). To our knowledge, the potential for reducing radiation dose for cryoablation patients.The principle aim of this study was to evaluate the effect on the radiation dose to the patient by reducing the tube current during the placement of the ablation needles (reduced dose group) compared with the patient doses delivered when scanning at the standard fully diagnostic level (full dose group) in CT-guided percutaneous cryoablation. 相似文献
2.
Sarah J. Welsh Nicola Thompson Anne Warren Andrew N. Priest Tristan Barrett Stephan Ursprung Ferdia A. Gallagher Fulvio Zaccagna Grant D. Stewart Kate M. Fife Athena Matakidou Andrea J. Machin Wendi Qian Victoria Ingleson Jean Mullin Antony C. P. Riddick James N. Armitage Stephen Connolly Timothy G. Q. Eisen 《BJU international》2022,130(2):244-253
3.
Hsin-Yi Tseng Jan Dreyer Abdullah Al Emran Dilini Gunatilake Mehdi Pirozyan Carleen Cullinane Ken Dutton-Regester Helen Rizos Nicholas K. Hayward Grant McArthur Peter Hersey Jessamy Tiffen Stuart Gallagher 《International journal of cancer. Journal international du cancer》2020,147(8):2176-2189
The treatment of melanoma has been markedly improved by the introduction of targeted therapies and checkpoint blockade immunotherapy. Unfortunately, resistance to these therapies remains a limitation. Novel anticancer therapeutics targeting the MCL1 anti-apoptotic protein have shown impressive responses in haematological cancers but are yet to be evaluated in melanoma. To assess the sensitivity of melanoma to new MCL1 inhibitors, we measured the response of 51 melanoma cell lines to the novel MCL1 inhibitor, S63845. Additionally, we assessed combination of this drug with inhibitors of the bromodomain and extra-terminal (BET) protein family of epigenetic readers, which we postulated would assist MCL1 inhibition by downregulating anti-apoptotic targets regulated by NF-kB such as BCLXL, BCL2A1 and XIAP, and by upregulating pro-apoptotic proteins including BIM and NOXA. Only 14% of melanoma cell lines showed sensitivity to S63845, however, combination of S63845 and I-BET151 induced highly synergistic apoptotic cell death in all melanoma lines tested and in an in vivo xenograft model. Cell death was dependent on caspases and BAX/BAK. Although the combination of drugs increased the BH3-only protein, BIM, and downregulated anti-apoptotic proteins such as BCL2A1, the importance of these proteins in inducing cell death varied between cell lines. ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL, respectively, induced further cell death when combined with S63845 and I-BET151. The combination of MCL1 and BET inhibition appears to be a promising therapeutic approach for metastatic melanoma, and presents opportunities to add further BCL2 family inhibitors to overcome treatment resistance. 相似文献
4.
5.
6.
Adam Tucker Seamus O’Brien Emer Doran Nicola Gallagher David E. Beverland 《The Journal of arthroplasty》2019,34(1):40-46.e1
Background
Valgus knee deformity accounts for only 10% of total knee arthroplasties (TKAs), but is frequently considered the most challenging to manage. This study provides a 10-year follow-up on a previously reported series of severe valgus knees performed using an unconstrained mobile-bearing TKA with a modified technique to validate this technique.Methods
A consecutive series of 275 predominantly cementless TKAs in 262 patients were performed for severe valgus (≥10°) deformity and prospectively followed to 10 years. Patient-reported outcome measures included the Oxford Knee Score, American Knee Society Score, Bartlett Patellar Score, and the Short Form 12 questionnaire.Results
Average valgus deformity was reduced from 15.6° to 3.8° (P < .001). At a mean follow-up of 10.4 years (range, 9.5-14.1), 90 (34.4%) patients had died. Of the reviewed survivors, the mean Oxford Knee Score was 27.8 ± 9.8, with an American Knee Society clinical score of 85.6 ± 17.0 and a functional score of 65.1 ± 20.4, with 78% of patients reporting good to excellent results. To date, there has been 1 (0.36%) revision and 13 (4.73%) reoperations. Kaplan-Meier implant survival was 99.6% at 10 years.Conclusion
Despite its challenging nature, the valgus knee is associated with excellent survivorship and satisfactory long-term results using this modified technique.Level of Evidence
Level IV. 相似文献7.
8.
9.
10.